Government fund backs chemistry start-up
Potential Sciences, a British startup working on AI-driven drug design, has secured backing from the UK Government’s Sovereign AI venture fund as part of an eight-figure funding round announced on Thursday 5 November, according to the Cabinet Office.
The support package combines investment with access to compute, the processing power needed to train and run AI models. The Cabinet Office says the backing reflects ministers’ ambition to grow homegrown AI companies in Britain as part of what it calls the “modern reindustrialisation” of the country.
What the technology does
Most AI models used in drug discovery rely on data from laboratory experiments, which the government says are slow and costly to produce, creating a bottleneck for research. Potential Sciences has built its model around the fundamental laws of physics instead of relying on that experimental data.
The Cabinet Office states this approach could make the AI calculations needed to design new chemicals up to 100 times cheaper than current methods. The government says this could open up research into diseases, including cancer and Parkinson’s, that are currently considered too expensive or rare to justify investment under existing approaches.
Sovereign AI fund’s role
Sovereign AI is the government’s vehicle for backing early-stage AI companies with the stated aim of helping them “grow, scale and succeed from Britain”. The Cabinet Office describes it as combining the pace of venture capital investment with state backing, intended to support AI entrepreneurs to compete globally while remaining based in the UK.
AI Minister Kanishka Narayan said Potential Sciences was seizing an opportunity Britain is “uniquely well-placed” to capitalise on, pointing to the country’s expertise in data, fundamental science and computing. He said solving chemistry’s “data bottleneck” could let researchers explore treatments for diseases currently seen as too rare or too expensive to pursue.
Science Minister Chris McDonald, a former chemical engineer, said the investment brought together British scientific research and AI, and that backing companies such as Potential Sciences was part of giving them “the support they need to realise their ambitions”.
What it means for the UK
The deal gives a concrete example of how the Sovereign AI fund operates in practice: a mix of direct investment and compute access aimed at keeping promising AI firms anchored in Britain rather than moving overseas for funding or infrastructure. For the wider UK life sciences and AI sector, it signals government willingness to put state money behind early-stage companies working on fundamental AI research rather than only established scale-ups.
The Cabinet Office release does not specify the exact size of the funding round beyond describing it as “eight-figure”, nor does it name other investors involved alongside Sovereign AI. It also does not set out a timeline for when Potential Sciences’ technology might move from research into practical drug discovery use.
What to watch next
Readers should watch for further detail on the full funding round, including whether private investors co-invested alongside Sovereign AI, and for any follow-up from Potential Sciences on research results or partnerships that test its physics-based approach against real-world drug targets.